A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL).

7529Background: Penpulimab is a humanized IgG1 monoclonal antibody (mAb) that blocks PD-1 binding to PD-L1. Penpulimab, with its unique binding epitope, was engineered to eliminate Fc-mediated effe...